JP2019513726A5 - - Google Patents

Download PDF

Info

Publication number
JP2019513726A5
JP2019513726A5 JP2018552076A JP2018552076A JP2019513726A5 JP 2019513726 A5 JP2019513726 A5 JP 2019513726A5 JP 2018552076 A JP2018552076 A JP 2018552076A JP 2018552076 A JP2018552076 A JP 2018552076A JP 2019513726 A5 JP2019513726 A5 JP 2019513726A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
acid sequence
cdr
sequence seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018552076A
Other languages
English (en)
Japanese (ja)
Other versions
JP6967528B2 (ja
JP2019513726A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/025784 external-priority patent/WO2017176651A1/en
Publication of JP2019513726A publication Critical patent/JP2019513726A/ja
Publication of JP2019513726A5 publication Critical patent/JP2019513726A5/ja
Priority to JP2021147485A priority Critical patent/JP7326393B2/ja
Application granted granted Critical
Publication of JP6967528B2 publication Critical patent/JP6967528B2/ja
Priority to JP2023126155A priority patent/JP2023139289A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018552076A 2016-04-04 2017-04-03 抗補体Ｂｂ因子抗体及びその使用 Active JP6967528B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021147485A JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用
JP2023126155A JP2023139289A (ja) 2016-04-04 2023-08-02 抗補体Ｂｂ因子抗体及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662317897P 2016-04-04 2016-04-04
US62/317,897 2016-04-04
PCT/US2017/025784 WO2017176651A1 (en) 2016-04-04 2017-04-03 Anti-complement factor bb antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021147485A Division JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2019513726A JP2019513726A (ja) 2019-05-30
JP2019513726A5 true JP2019513726A5 (enExample) 2020-05-07
JP6967528B2 JP6967528B2 (ja) 2021-11-17

Family

ID=60000646

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018552076A Active JP6967528B2 (ja) 2016-04-04 2017-04-03 抗補体Ｂｂ因子抗体及びその使用
JP2021147485A Active JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用
JP2023126155A Pending JP2023139289A (ja) 2016-04-04 2023-08-02 抗補体Ｂｂ因子抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021147485A Active JP7326393B2 (ja) 2016-04-04 2021-09-10 抗補体Ｂｂ因子抗体及びその使用
JP2023126155A Pending JP2023139289A (ja) 2016-04-04 2023-08-02 抗補体Ｂｂ因子抗体及びその使用

Country Status (23)

Country Link
US (3) US10934347B2 (enExample)
EP (1) EP3452510A4 (enExample)
JP (3) JP6967528B2 (enExample)
KR (2) KR102673420B1 (enExample)
CN (2) CN109563158B (enExample)
AU (2) AU2017246794B2 (enExample)
BR (1) BR112018070357A2 (enExample)
CA (1) CA3019332A1 (enExample)
CL (1) CL2018002810A1 (enExample)
CO (1) CO2018010827A2 (enExample)
CR (1) CR20180529A (enExample)
DO (1) DOP2018000219A (enExample)
EA (1) EA201892225A1 (enExample)
EC (1) ECSP18082302A (enExample)
IL (3) IL311675A (enExample)
MA (1) MA44878A (enExample)
MX (2) MX2018012176A (enExample)
MY (1) MY194603A (enExample)
PE (1) PE20190209A1 (enExample)
PH (1) PH12018502137A1 (enExample)
SG (1) SG11201808525UA (enExample)
TN (1) TN2018000341A1 (enExample)
WO (1) WO2017176651A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011282579B2 (en) 2010-07-28 2014-10-23 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin Fc compositions
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
US10934347B2 (en) 2016-04-04 2021-03-02 Genzyme Corporation Anti-complement factor BB antibodies and uses thereof
KR102729723B1 (ko) 2016-12-09 2024-11-15 글리크닉 인코포레이티드 다합체화 스트라도머인 gl-2045의 제조 최적화
JP7519774B2 (ja) * 2016-12-09 2024-07-22 グリックニック インコーポレイテッド 多価ｆｃ化合物を用いる炎症性疾患の治療方法
US11690919B2 (en) * 2017-01-17 2023-07-04 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
EP3728568A4 (en) 2017-12-19 2021-10-06 The University of North Carolina at Chapel Hill METHODS AND COMPOSITIONS FOR DELIVERING VIRAL VECTORS BY THE BLOOD-BRAIN BARRIER
JP2022540768A (ja) * 2019-06-27 2022-09-20 ヴェルソー セラピューティクス， インコーポレイテッド 骨髄細胞炎症性表現型を調節するための抗ｃｄ５３組成物及び方法、ならびにその使用
BR112022000739A2 (pt) * 2019-07-17 2022-04-12 Gemini Therapeutics Sub Inc Anticorpos de potencialização de fator h e usos dos mesmos
US20230050339A1 (en) * 2020-02-18 2023-02-16 Children's Hospital Medical Center Compositions and methods for treating liver disease
WO2021216458A1 (en) * 2020-04-20 2021-10-28 Genzyme Corporation Humanized anti-complement factor bb antibodies and uses thereof
JP7787164B2 (ja) 2020-09-23 2025-12-16 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体媒介性障害の治療のための医薬化合物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
KR100551104B1 (ko) 1994-12-09 2006-02-09 임페리얼 컬리지 이노베이션스 리미티드 유전자의 동정
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP4162267B2 (ja) 1996-08-27 2008-10-08 カイロン コーポレイション Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ血清型Ｂ複合糖質およびその使用法
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
AR014621A1 (es) 1997-12-12 2001-03-28 Macromed Inc Un poli (etilenglicol) con forma de estrella, heterofuncional, biocompatible, metodo para su obtencion y metodo para conjugarlo con una proteina
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
AU2005212369B2 (en) 2004-02-10 2011-06-23 Musc Foundation For Research Development Inhibition of factor B, the alternative complement pathway and methods related thereto
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
HUE026423T2 (en) 2005-11-04 2016-05-30 Genentech Inc Use of complement biosynthetic pathway inhibitors for treating eye diseases
MX2008007682A (es) 2005-12-20 2008-10-23 Sbi Biotech Co Ltd Anticuerpo anti-ilt7.
CN101970002B (zh) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
BRPI0820343A2 (pt) * 2007-11-08 2017-08-22 Genentech Inc Anticorpos de antifator b e seus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
BRPI0923283A2 (pt) 2008-12-05 2017-06-06 Angiochem Inc conjugados terapêuticos de peptídeo e usos dos mesmos
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
HK1199405A1 (en) 2011-10-27 2015-07-03 Nkt治疗公司 Humanized antibodies to inkt
EP3093294A1 (en) * 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use
JP6244350B2 (ja) * 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
WO2014044793A2 (en) 2012-09-20 2014-03-27 Max-Delbrück-Centrum für Molekulare Medizin Cd22-binding peptides
CA2889197A1 (en) * 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
US10035847B2 (en) * 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
SG11201606983SA (en) 2014-02-27 2016-09-29 Allergan Inc COMPLEMENT FACTOR Bb ANTIBODIES
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
US10934347B2 (en) 2016-04-04 2021-03-02 Genzyme Corporation Anti-complement factor BB antibodies and uses thereof
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
WO2021216458A1 (en) 2020-04-20 2021-10-28 Genzyme Corporation Humanized anti-complement factor bb antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2019513726A5 (enExample)
RU2755724C2 (ru) Pd1/ctla4-связывающие вещества
TWI384997B (zh) 抗酪胺酸酶相關蛋白-１（ｔｙｒｐ１）抗體
JP2019505527A5 (enExample)
AU2017376884B2 (en) Stable aqueous anti-C5 antibody composition
JP2014158469A5 (enExample)
US20180142010A1 (en) Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
US9932397B2 (en) VEGFA/Ang2 Compounds
KR20200020902A (ko) 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2015503909A5 (enExample)
CN114502595B (zh) 针对脊髓灰质炎病毒受体(pvr)的抗体及其用途
JP2021510523A5 (enExample)
JP2018533569A5 (enExample)
WO2019076277A1 (zh) 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
JP2018529661A5 (enExample)
JP2017515843A5 (enExample)
CN111683681A (zh) 包含抗ox40抗体的制剂、其制备方法及其用途
CN107249630A (zh) 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重
WO2010094981A2 (en) Antibody therapy
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
EP3164154A1 (en) Combination therapy
EP3280732B1 (en) Antibodies binding to canine vascular endothelial growth factor and uses thereof in treating canine angiogenesis-related diseases
US20240287169A1 (en) Methods of use of anti-il-2 antibodies